trending Market Intelligence /marketintelligence/en/news-insights/trending/QzhUoriWljKJHS06BS_rpg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Maxigen Biotech Q2 loss narrows YOY


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 3: Transformation of Customer Experience in 2020

Maxigen Biotech Q2 loss narrows YOY

Maxigen Biotech Inc. said its normalized net income for the second quarter amounted to a loss of 1 Taiwan cents per share, compared with a loss of 14 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$889,380, compared with a loss of NT$10.2 million in the year-earlier period.

The normalized profit margin climbed to negative 1.1% from negative 13.7% in the year-earlier period.

Total revenue increased 8.7% year over year to NT$80.6 million from NT$74.1 million, and total operating expenses fell 9.9% year over year to NT$81.7 million from NT$90.7 million.

Reported net income totaled a loss of NT$3.5 million, or a loss of 5 cents per share, compared to a loss of NT$15.6 million, or a loss of 22 cents per share, in the prior-year period.

As of Aug. 12, US$1 was equivalent to NT$31.39.